Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1986 1
1989 1
1990 1
1991 1
1992 1
1994 1
1995 1
1996 2
1998 2
2001 1
2003 5
2004 2
2005 3
2006 1
2007 1
2008 2
2009 3
2010 17
2011 10
2012 9
2013 7
2014 10
2015 7
2016 5
2017 10
2018 20
2019 16
2020 13
2021 13
2022 9
2023 10
2024 9
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Eikelboom JW, et al. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844192 Free article. Clinical Trial.
Classification of GBA1 variants and their impact on Parkinson's disease: an in silico score analysis.
Lanore A, Tesson C, Basset A, Lejeune FX, Cogan G, Mangone G, Sambin S, Bertille N, Anheim M, Arnulf I, Ansquer S, Brandel JP, Brefel-Courbon C, Defebvre L, Drapier S, Eusebsio A, Fabbri M, Giordana C, Hainque E, Lehericy S, Marques A, Moreau C, Moro E, Ory F, Rolland AS, Thobois S, Vidailhet M, Devos D, Mariani LL, Lesage S, Brice A, Corvol JC; Predistim study group; Iceberg study group; NSPark study group. Lanore A, et al. NPJ Parkinsons Dis. 2025 Aug 2;11(1):226. doi: 10.1038/s41531-025-01060-6. NPJ Parkinsons Dis. 2025. PMID: 40753162 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population.
Paz-Graniel I, Babio N, Becerra-Tomás N, Toledo E, Camacho-Barcia L, Corella D, Castañer-Niño O, Romaguera D, Vioque J, Alonso-Gómez ÁM, Wärnberg J, Martínez JA, Serra-Majem L, Estruch R, Tinahones FJ, Fernandez-Aranda F, Lapetra J, Pintó X, Tur JA, García-Rios A, Bueno-Cavanillas A, Gaforio JJ, Matía-Martín P, Daimiel L, Sánchez VM, Vidal J, Prieto-Sanchez L, Ros E, Razquin C, Mestres C, Sorli JV, Cuenca-Royo AM, Rios A, Torres-Collado L, Vaquero-Luna J, Pérez-Farinós N, Zulet MA, Sanchez-Villegas A, Casas R, Bernal-Lopez MR, Santos-Lozano JM, Corbella X, Mateos D, Buil-Cosiales P, Jiménez-Murcia S, Fernandez-Carrion R, Forcano-Gamazo L, López M, Sempere-Pascual MÁ, Moreno-Rodriguez A, Gea A, de la Torre-Fornell R, Salas-Salvadó J; PREDIMED-Plus Investigators. Paz-Graniel I, et al. Eur J Nutr. 2021 Aug;60(5):2381-2396. doi: 10.1007/s00394-020-02415-w. Epub 2020 Oct 30. Eur J Nutr. 2021. PMID: 33125576
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
ON/OFF non-motor evaluation: a new way to evaluate non-motor fluctuations in Parkinson's disease.
Faggianelli F, Witjas T, Azulay JP, Benatru I, Hubsch C, Anheim M, Moreau C, Hainque E, Drapier S, Jarraya B, Laurencin C, Guehl D, Hopes L, Brefel-Courbon C, Tir M, Marques A, Rouaud T, Maltete D, Giordana C, Baumstarck K, Rascol O, Corvol JC, Rolland AS, Devos D, Eusebio A; PREDISTIM study group. Faggianelli F, et al. J Neurol Neurosurg Psychiatry. 2024 Jun 17;95(7):656-662. doi: 10.1136/jnnp-2023-332551. J Neurol Neurosurg Psychiatry. 2024. PMID: 38272656
Monitoring the phenology of plant pathogenic fungi: why and how?
Delmas CEL, Bancal MO, Leyronas C, Robin MH, Vidal T, Launay M. Delmas CEL, et al. Among authors: vidal t. Biol Rev Camb Philos Soc. 2024 Jun;99(3):1075-1084. doi: 10.1111/brv.13058. Epub 2024 Jan 29. Biol Rev Camb Philos Soc. 2024. PMID: 38287495 Free article. Review.
177 results